CS
TVRD

Candriam SCA’s Tvardi Therapeutics TVRD Stock Holding History

Candriam SCA’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,990
Closed -$769K – 941
2022
Q4 		$769K Sell
1,990
-525
-21% -$199K 0.01% 753
2022
Q3 		$848K Buy
+2,515
New +$911K 0.01% 744

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Candriam SCA's TVRD Position: Q1 2023 in Review

Candriam SCA sold out of Tvardi Therapeutics (TVRD) in Q1 2023, closing a stake of 1,990 shares — an estimated $769K sold.

Candriam SCA first reported a position in TVRD in Q3 2022 and held it in 2 quarters. The position peaked at $848K in Q3 2022. 163 funds tracked by Wall St. Rank hold TVRD as of Q1 2023.

  • Candriam SCA reported no remaining Tvardi Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Candriam SCA sold 1,990 Tvardi Therapeutics shares in Q1 2023, an estimated $769K.
  • Candriam SCA first reported a position in Tvardi Therapeutics in Q3 2022 and held it in 2 quarters.
  • Candriam SCA's Tvardi Therapeutics position peaked at $848K in Q3 2022.
  • 163 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2023.

Based on Candriam SCA's 13F filing for Q1 2023, filed 12 May 2023.